title: [Interferon-based immunobiological preparations. An outlook of their use in the treatment of patients with infections].
abstract: The paper contains the generalizing results of many-year research related with using various ready-made medication forms (RMF) of human genetic-engineering interferon-alpha 2 and of methods of its administration into the body. Extensive clinical materials were made use of to show convincingly that the most effective therapy for infectious diseases is ensured within a short time period and with a consequent long-term rehabilitation effect by using separate RMFs and methods of application of interferon-alpha 2, when their impact on the lesion focus is monitored by the parameters of the cellular-and-humoral chains of the general and local immunity. It is noteworthy, that a selection of RMF adequate for an actual nosologic form or of an administration method can reduce the medication dose of interferon-alpha 2 (thus, the incidence of complications to the drug goes down), it can also eliminate the influenza-like syndrome and production of autoantibodies related with the intramuscular administration of interferon-alpha 2, besides, it essentially prolongs the presence of interferon-alpha 2 in the body. It is important that the application of interferon-based preparations for infectious diseases can eliminate, in a number of cases, the use of antibiotics and other antibacterial drugs, it enhances the efficacy of antibacterial and antiviral therapy within a comprehensive treatment scheme, it contributes to a higher resistance of normal flora to the action of antibiotic and antibacterial drugs, and, finally, it arrests quicker the manifestations of dysbacterioses of various localizations.
authors.forename: S S
authors.initials: SS
authors.lastname: Afanas'ev
authors.forename: V A
authors.initials: VA
authors.lastname: Aleshkin
authors.forename: L V
authors.initials: LV
authors.lastname: Feklisova
authors.forename: O V
authors.initials: OV
authors.lastname: Rubal'skiĭ
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Davydkin
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007223:Infant; D007239:Infections / Q000188:drug therapy*; D007273:Injections, Intramuscular; D016898:Interferon-alpha / Q000008:administration & dosage*; D007410:Intestinal Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010612:Pharyngitis / Q000188:drug therapy; D015202:Protein Engineering; D012008:Recurrence; D012106:Research; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013488:Suppositories; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D013488:Suppositories